Clinical Trials on Endometritis in Japan

Total 22 results

Bayer

Completed

Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea

Endometriosis and Dysmenorrhea

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

Endometriosis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

Endometriosis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)

Endometriosis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)

Endometriosis

Japan
Bayer

Completed

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Japan
ASKA Pharmaceutical Co., Ltd.

Completed

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

Endometriosis

Japan
Mylan Inc.

Completed

A Survey on Efficacy and Safety in Patients With Endometriosis

Endometriosis

Japan
University of Patras

Completed

GnRH-a on Angiogenesis of Endometriosis

Endometriosis | Angiogenesis

Greece, Japan
Bayer

Completed

Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

Endometriosis

Japan
Bayer

Terminated

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis (VILLENDO)

Endometriosis

United States, Austria, Japan, Poland, Finland, Canada, Italy, Czechia
Takeda

Completed

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Endometriosis

Japan
Takeda

Completed

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

Endometriosis

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain

Endometriosis

Belgium, Bulgaria, Germany, Hungary, Japan, Poland, Romania, Ukraine, United Kingdom
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Bayer

Completed

Bay98-7196, Dose Finding / POC Study

Endometriosis

Belgium, Finland, Switzerland, Germany, Spain, Japan, United States, Canada, Austria, Czechia, Denmark, Netherlands, Poland, Norway
Bayer

Terminated

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb (SCHUMANN)

Endometriosis

Spain, Belgium, United States, Germany, Austria, Japan, Canada, Hungary, Bulgaria, Italy, China, Czechia, Finland, Norway, Poland, Slovakia, Estonia, Greece, Latvia, Lithuania
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan

Clinical Trials on Endometritis in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations